Gsa Capital Partners LLP Pacira Bio Sciences, Inc. Transaction History
Gsa Capital Partners LLP
- $1.11 Billion
- Q1 2025
A detailed history of Gsa Capital Partners LLP transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 10,973 shares of PCRX stock, worth $267,082. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,973Holding current value
$267,082% of portfolio
0.02%Shares
12 transactions
Others Institutions Holding PCRX
# of Institutions
254Shares Held
51.1MCall Options Held
157KPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$195 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.24MShares$128 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$55.1 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.24MShares$54.5 Million0.09% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.05MShares$49.9 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.12B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...